Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Mineralys Therapeutics Inc shares valued at $173,774 were sold by Rodman David Malcom on May 14 ’25. At $15.29 per share, Rodman David Malcom sold 11,366 shares. The insider’s holdings dropped to 106,669 shares worth approximately $1.66 million following the completion of this transaction.
Also, Rodman David Malcom purchased 11,366 shares, netting a total of over 173,774 in proceeds.
Before that, Slingsby Brian Taylor had added 259,259 shares to its account. In a trade valued at $3,499,996, the Director bought Mineralys Therapeutics Inc shares for $13.50 each. Upon closing the transaction, the insider’s holdings increased to 259,259 shares, worth approximately $138.19 million.
As published in their initiating research note from H.C. Wainwright on July 10, 2024, Mineralys Therapeutics Inc [MLYS] has been a Buy and the price target has been revised to $30. Analysts at Goldman started covering the stock with ‘”a Buy”‘ outlook in a report released in early April. As of March 07, 2023, Wells Fargo has initiated its “an Overweight” rating for MLYS. Earlier on March 07, 2023, Stifel initiated its rating. Their recommendation was “a Buy” for MLYS stock.
Analyzing MLYS Stock Performance
During the last five days, there has been a drop of approximately -2.02%. Over the course of the year, Mineralys Therapeutics Inc shares have jumped approximately 26.08%. Shares of the company reached a 52-week high of $18.38 on 03/19/25 and a 52-week low of $8.24 on 02/25/25.
Support And Resistance Levels for Mineralys Therapeutics Inc (MLYS)
According to the 24-hour chart, there is a support level at 15.16, which, if violated, would cause prices to drop to 14.79. In the upper region, resistance lies at 16.16. The next price resistance is at 16.79. RSI (Relative Strength Index) is 52.36 on the 14-day chart, showing neutral technical sentiment.
